Key result
A 12-week allisartan isoproxil-based antihypertensive regimen effectively reduced blood pressure in patients with mild-to-moderate essential hypertension, achieving an overall control rate of 78.56%.
Why the study?
This study aimed to assess the clinical efficacy of allisartan isoproxil, a selective nonpeptide AT1 receptor blocker developed in China, for essential hypertension.
Does an allisartan isoproxil-based regimen reduce blood pressure in patients with mild-to-moderate essential hypertension?
RCT (n=2,126)
1:1
Yes
Does an allisartan isoproxil-based regimen reduce blood pressure in patients with mild-to-moderate essential hypertension?
An allisartan isoproxil-based regimen, either as monotherapy or in combination with indapamide or amlodipine, effectively reduces blood pressure in patients with mild-to-moderate essential hypertension.
Supports allisartan isoproxil regimens for mild-to-moderate hypertension; extends RCT evidence for this ARB.
BACKGROUND: Allisartan isoproxil is a selective nonpeptide angiotensin II (AT1) receptor blocker developed by China, this study aimed to assess its clinical efficacy for essential hypertension (EH). METHODS: Patients with mild-to-moderate EH, selected at 44 sites in China from September 9, 2016, to December 7, 2018, were administered 240 mg allisartan isoproxil daily for 4 weeks. Patients with controlled blood pressure (BP) continued monotherapy for 8 weeks, others were randomly assigned (1:1) to A + D group (allisartan isoproxil 240 mg + indapamide 1.5 mg) or A + C group (allisartan isoproxil + amlodipine besylate 5 mg) for 8 weeks. BP were measured at week 4, 8 and 12. RESULTS: 2,126 patients were included in the analysis. After 12 weeks of treatment, systolic blood pressure (SBP) and diastolic blood pressure (DBP) decreased by 19.24 ± 12.02 and 10.63 ± 8.89 mm Hg, respectively, and the overall BP control rate was 78.56%. The sitting blood pressures (SBP/DBP) decreased by 19.12 ± 11.71/10.84 ± 8.73 mm Hg in patients with 12 weeks allisartan isoproxil monotherapy (both P < 0.0001). The BP reductions and control rates were comparable between A + D and A + C groups. 48 patients with monotherapy-controlled BP underwent ambulatory BP monitoring, with a mean decrease in ambulatory BP of 10.04 ± 10.87/5.50 ± 8.07 mm Hg after 12 weeks of treatment, and consistent reductions between day and night. SBP and DBP had trough-to-peak ratios of 64.64% and 62.63% and smoothness indices of 3.82 and 2.92, respectively. CONCLUSIONS: An allisartan isoproxil-based antihypertensive regimen can effectively control BP in patients with mild-to-moderate EH. PROJECT REGISTRATION NO: CTR20160138 (Registration and Information Disclosure Platform for China Drug Clinical Studies, http://www.chinadrugtrials.org.cn/index.html).
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) conducted an RCT in Mild-to-moderate essential hypertension (n=2,126). Allisartan isoproxil was evaluated on Overall blood pressure control rate. A 12-week allisartan isoproxil-based antihypertensive regimen effectively reduced blood pressure in patients with mild-to-moderate essential hypertension, achieving an overall control rate of 78.56%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: